Plasma concentration of atrial natriuretic polypeptide in chronic hemodialysis patients

Yamamoto, Yoshitaka; Higa, Toshinobu; Kïtamura, Kazuo; Tanaka, Kenjiro; Kangawa, Kenji; Matsuo, Hisayuki

doi:10.1016/0167-0115(85)90231-9

Cited by 15 publications

(16 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…a.a. 1-98) of the ANF prohormone pre-and posthemodi alysis in each of the 13 individuals with chronic renal failure are illustrated in figure 2. Instead of a decrease in the circulating N-terminus concentration postdialysis as has been observed with ANF [10][11][12][13][14][15][16][17][18][19], there was an 18% increase after dialysis. As observed in figure 2, when the individual predialysis values are paired with their postdi alysis values, there was not a single individual in whom the N-terminus concentration decreased after hemodi alysis.…”

Section: Resultsmentioning

confidence: 92%

See 1 more Smart Citation

Change in Plasma Immunoreactive N-Terminus, C-Terminus, and 4,000-Dalton Midportion of Atrial Natriuretic Factor Prohormone with Hemodialysis

Winters

Vesely²

1991

Nephron

View full text Add to dashboard Cite

Plasma concentrations of the immunoreactive N-terminus, C-terminus and 4,000-dalton midportion of the N-terminus of the atrial natriuretic factor (ANF) prohormone were measured before and after hemodialysis in 13 patients with end-stage renal disease. There was a significant (p < 0.001) fall in the mean plasma concentration of the C-terminus (i.e. ANF, amino acids 99–126 of the prohormone) from 123 ± 25 to 80 ± 22 fmol/ml (mean ± SEM) with dialysis. The whole N-terminus, on the other hand, increased from 9,336 ± 2,011 to 11,021 ± 2,134 fmol/ml after dialysis (p < 0.002). Pro ANF 31–67 (i.e. amino acids 31–67 of the prohormone) increased postdialysis from 27,775 ± 4,300 to 31,040 ± 4,840 fmol/ml (p < 0.003). Only 1.5% of pro ANF 1–98 and pro ANF 31–67 were cleared by the dialyzer membrane while 15% of ANF crossed the membrane. Thus, with hemodialysis the C-terminus decreases while the N-terminus and pro ANF 31–67 from the midportion of the N-terminus of the ANF prohormone increase in plasma which is partially explained by their respective abilities to cross the dialyzer membrane.

show abstract

Section: Resultsmentioning

confidence: 92%

“…Hemodialysis has been reported to decrease the circu lating concentration of ANF, a 3,081 molecular weight (mw) peptide [10][11][12][13][14][15][16][17][18][19]. The recent discovery that pro ANF 31-67 from the midportion of the N-Terminus ( fig.…”

Section: Introductionmentioning

confidence: 99%

Change in Plasma Immunoreactive N-Terminus, C-Terminus, and 4,000-Dalton Midportion of Atrial Natriuretic Factor Prohormone with Hemodialysis

Winters

Vesely²

1991

Nephron

View full text Add to dashboard Cite

show abstract

“…Indeed, abnormally high levels of circulat ing ANP have been found in patients with the syndrome of inappropriate secretion of antidiuretic hormone [70,71], primary aldosteronism [72,73], congestive heart failure [74,75], and chronic renal failure [76,77], Fur thermore, abnormally high plasma ANP levels decline in patients as their congestive heart failure is treated [78] and as the excess fluid accumulated during renal failure is removed by hemodialysis [79][80][81]. Patients with par oxysmal atrial tachycardia often develop an increase in atrial pressure during the tachycardia as well as an increase in plasma ANP [82][83][84],…”

Section: Relationship Between Changes In Circulating Bloodmentioning

confidence: 99%

Effects of Water Immersion on Atrial Natriuretic Peptide Release in Humans

Epstein

Norsk²,

Loutzenhiser³

1989

Am J Nephrol

View full text Add to dashboard Cite

Water immersion (WI) to the neck induces prompt increases in central blood volume, central venous pressure, and atrial distension. Since atrial distension is a major stimulus for atrial natriuretic peptide (ANP) release, WI constitutes a unique model to investigate the physiological importance of ANP in humans. All studies to date demonstrate that ANP increases during the 1st h of WI in hydrated subjects, rising 2.5- to 3-fold by the end of the 2nd or 3rd h. During recovery from WI, ANP returns promptly to prestudy levels. Although distension of the atria probably constitutes the major stimulus for ANP release during WI, other mechanisms may coexist. In normal hydrated subjects undergoing WI, the increases in ANP correlate with the magnitude of the natriuresis, suggesting that ANP constitutes an important determinant of renal sodium handling in humans. It is simplistic, however, to consider the Wl-induced augmentation of ANP to be the sole, or even the prepotent, mediator of the resultant natriuresis. Rather ANP should be considered as one of several hormonal, neural, and hemodynamic factors acting in concert in an integrated matrix to modulate volume homeostasis. Clearly, the results of several recent studies utilizing WI demonstrate that this maneuver constitutes an important investigative model to delineate further the role of ANP in subserving volume homeostasis in normal humans and in disorders of deranged volume regulation.

show abstract

“…The primary stimulus for the cardiac release of atrial natriuretic peptide (ANP) is increased stretch of atrial myocytes [1], which is usually a consequence of increased atrial pressure due to either increased circulating plasma volume [2,3] or to congestive heart failure [4]. Several studies employing radioimmunoassay have confirmed that plasma concentrations of immunoreactive ANP are considerably elevated in patients with end-stage renal disease [5][6][7][8][9][10] and may be reduced by haemodialysis [6,7] or ultrafiltration [7,8,10]. The conclusion has been drawn that raised concentrations of ANP in end-stage renal disease are entirely due to plasma volume overload [5,10], which may be corrected by dialysis or ultrafiltration.…”

Section: Introductionmentioning

confidence: 99%

Comparative Effects of Haemodialysis and Haemofiltration on Plasma Atrial Natriuretic Peptide

Raine

Böck

Müller

et al. 1989

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

The effects of 4 h haemodialysis (15 patients) or 4 h haemofiltration (five patients) on plasma concentrations of atrial natriuretic peptide (ANP) were compared by means of a sensitive radioreceptor binding assay, and related to accompanying changes in body weight, blood pressure and plasma renin activity. Before dialysis, plasma ANP concentrations were considerably elevated: haemodialysis group 10-484 pmol/l (mean 156 pmol/l); haemofiltration group 72-320 pmol/l (mean 170 pmol/l). Although plasma concentrations of ANP fell markedly with treatment in both groups: post-haemodialysis 2-187 pmol/l (mean 67 pmol/l); post-haemofiltration 47-135 pmol/l (mean 79 pmol/l), after treatment it remained above the normal range in 14 of the 20 patients. Pretreatment plasma ANP was related to systolic blood pressure (r = 0.459; P less than 0.05) but bore no relationship to mean or diastolic blood pressure, or plasma renin activity. The fall in plasma ANP concentration during treatment correlated with the postural blood pressure drop after dialysis (r = 0.505; P less than 0.05), but was unrelated to changes in weight or plasma renin activity with haemodialysis or haemofiltration. Plasma ANP concentrations rose rapidly again in the 60 min after dialysis treatment, without change in body weight. These results show that high levels of biologically active ANP circulate in end-stage renal disease. The fact that these are not reduced to normal by haemodialysis or haemofiltration, despite restoration to normovolaemic or hypovolaemic state, suggests that the increased levels of ANP in end-stage renal failure are due to both hypervolaemia and other factors, which may include occult cardiac dysfunction and loss of renal clearance.

show abstract

Plasma concentration of atrial natriuretic polypeptide in chronic hemodialysis patients

Cited by 15 publications

References 3 publications

Change in Plasma Immunoreactive N-Terminus, C-Terminus, and 4,000-Dalton Midportion of Atrial Natriuretic Factor Prohormone with Hemodialysis

Change in Plasma Immunoreactive N-Terminus, C-Terminus, and 4,000-Dalton Midportion of Atrial Natriuretic Factor Prohormone with Hemodialysis

Effects of Water Immersion on Atrial Natriuretic Peptide Release in Humans

Comparative Effects of Haemodialysis and Haemofiltration on Plasma Atrial Natriuretic Peptide

Contact Info

Product

Resources

About